- 61.4% (56,781,354) of eligible shares voted
- 94.4% of votes were cast in favor of the resolution
RADNOR,
Pa., March 21, 2024 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced the results of the vote held during today's Special
Meeting of Shareholders.
The meeting was called to vote on a proposal to give the
Company's Board of Directors authority to effect a reverse stock
split of all of the outstanding shares of NRx common stock at a
ratio in the range of 1-for-2 to 1-for-15, with such ratio to be
determined by the Board in its discretion and included in a public
announcement, at a later date. Despite an active campaign by
internet agents to suppress the vote, 61.4% (56,781,354) of all
eligible shares were voted, with 94.4% (53,597,974) of votes cast
in favor of the proposal.
"We deeply appreciate and respect the support of our shareholder
base and look forward to continuing to bring hope to life," said
Jonathan Javitt, MD, MPH, Founder,
Chairman, and Chief Scientist of NRx Pharmaceuticals. "We thank our
detractors on the internet and elsewhere who have campaigned
tirelessly for our demise and, in the process, enabled our
investors to recognize the potential lifesaving value of our
technology. We look forward to sharing our annual report with
shareholders on March 28 and to
updating our investors on our ongoing progress."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen and Lotus around the
development and marketing of NRX-101 for the treatment of suicidal
bipolar depression. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced plans to submit a New Drug
Application for HTX-100 (IV ketamine), through Hope Therapeutics,
in the treatment of suicidal depression, based on results of
well-controlled clinical trials conducted under the auspices of the
US National Institutes of Health and newly obtained data from
French health authorities, licensed under a data sharing agreement.
NRx was awarded Fast Track Designation for development of ketamine
(NRX-100) by the US FDA as part of a protocol to treat patients
with acute suicidality.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-results-of-the-vote-held-during-the-special-meeting-of-shareholders-302096307.html
SOURCE NRx Pharmaceuticals, Inc.